The Clinical Trials Support Office (CTSO), Michigan Clinical Research Unit (MCRU), and Central Biorepository (CBR) have created the Emphasis on COVID-19-Related Research Biorepository to collect, process, and archive biospecimens from both residual clinical samples and prospective participants with SARS-CoV2 infection. The coordinated effort allows us to centralize recruitment and sample collection efforts in order to minimize staff exposure, reduce burden on patients and their families, conserve PPE, and facilitate timely and equitable access to samples for researchers.
The COVID-19 Biorepository provides faculty with valuable opportunities for understanding the effects of and response to SARS-CoV2 infection, COVID-19 mechanisms of disease, and virus epidemiology, among other biomedical insights, all of which can improve outcomes for infected individuals, and public health overall.
We are currently collecting plasma, serum, and whole cells (buffy coat) on a daily basis, and have collected thousands of residual serum and plasma samples from clinical blood draws. Samples are dependent on availability and sample types are evolving. We are currently working on processes to collect fresh samples (less than 4 hours post collection) and convalescent samples. To view a current inventory of what is available view the CBR Inventory (updated weekly) and DataDirect.
To learn more about how to access samples, click here.
